News

Filter

Current filters:

ImmunologicalsMerck & Co

1 to 9 of 15 results

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

05-03-2014

Pharma giant Merck & Co has announced results from a Phase IIb study evaluating two doses of its investigational…

ImmunologicalsMerck & CoPharmaceuticalResearchUSA

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

28-01-2014

The US Food and Drug Administration’s Allergenic Products Advisory Committee has voted that the available…

Alk-AbelloImmunologicalsMerck & CoNorth AmericaPharmaceuticalRagwitekRegulationUSA

Unanimous FDA panel support for Merck & Co’s Grastek

Unanimous FDA panel support for Merck & Co’s Grastek

13-12-2013

The Allergenic Products Advisory Committee (APAC) of the US Food and Drug Administration yesterday voted…

Alk-AbelloGrastekGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

ALK and Merck Co’s grass allergy tablet finally reaches FDA committee

ALK and Merck Co’s grass allergy tablet finally reaches FDA committee

10-12-2013

The US Food and Drug Administration Allergenic Products Advisory Committee will review US pharma giant…

ALK AbelloImmunologicalsMerck & CoPharmaceuticalRegulationUSA

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

12-11-2013

US pharma giant Merck & Co (NYSE: MRK) has published positive results for its investigational Timothy…

ALK AbelloGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalResearchUSA

US FDA accepts Merck & Co's BLA ragweed pollen allergy immunotherapy

09-05-2013

US pharma giant Merck & Co (NYSE: MRK) revealed yesterday (May 8) that the Biologics License Application…

Alk-AbelloBiotechnologyImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

US FDA accepts Merck & Co's BLA for Timothy grass pollen allergy product

27-03-2013

US pharma giant Merck & Co (NYSE: MRK) says that its Biologics License Application for the investigational…

ALK AbelloGrazaxImmunologicalsMerck & CoPharmaceuticalRegulationRespiratory and Pulmonary

1 to 9 of 15 results

Back to top